Nanjing Libowei Pharmaceutical

Nanjing Libowei Pharmaceutical is a biopharmaceutical company based in Nanjing, China, dedicated to the discovery, development, and commercialization of innovative small molecule drugs and high-end generics. The company's primary therapeutic focus includes oncology, cardiovascular diseases, and metabolic disorders. Its lead innovative candidate, LBW-001, is a multi-target kinase inhibitor currently in Phase 2 clinical trials for the treatment of various solid tumors. Libowei operates integrated R&D centers and GMP-compliant manufacturing facilities, enabling a full-spectrum approach from drug design to large-scale production. The company aims to address unmet medical needs by providing high-quality, affordable therapeutic solutions to patients globally.